By Adria Calatayud

 

Shares in NetScientific PLC (NSCI.LN) rose Thursday after it said portfolio company PDS Biotechnology Corp. (PDSB) will collaborate with U.S. drug maker Merck & Co. Inc. (MRK) in a phase II clinical trial.

NetScientific, a London-based healthcare technology company, said the trial will study PDS's lead product, PDS0101, in combination with Merck's cancer drug Keytruda as a first line treatment in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 infection.

Shares in NetScientific at 1256 GMT were up 40% at 8.75 pence.

 

Write to Adria Calatayud at adria.calatayudvaello@dowjones.com

 

(END) Dow Jones Newswires

October 03, 2019 09:13 ET (13:13 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Merck
Merck (NYSE:MRK)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Merck